24 July 2014
EMA/440911/2014

Overview of (invented) names reviewed in July 2014 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 21 - 24 July 2014

	NRG meeting 29 Jan 2014		NRG meeting 26 Mar 2014		NRG meeting 15 May 2014		NRG meeting 02 July 2014		NRG meeting 01 Oct 2014		NRG meeting 26 Nov 2014		2014	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed invented names	35	37	47	41	54	32	61	54						
Justification for retention of invented name *	1	6	0	5	1	9	2	4						

*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8427 **Facsimile** +44 (0)20 7418 8409
E-mail press@ema.europa.eu **Website** www.ema.europa.eu

	NRG meeting 29 Jan 2014		NRG meeting 26 Mar 2014		NRG meeting 15 May 2014		NRG meeting 02 July 2014		NRG meeting 01 Oct 2013		NRG meeting 26 Nov 2014		2014	
Objections	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	76	45	82	53	47	38	114	65						
Criterion - Safety concerns														
Similarity with other Invented name	62	36	72	46	42	28	96	53						
Conveys misleading therapeutic/pharmaceutical connotations		1		1		1	1							
Misleading with respect to composition						2								
Criterion - INN concerns														
Similarity with INN	4	1	4	2	2	1	9	3						
Inclusion of INN stem	3		4	3		1	3							
Criterion - Other public health concerns														
Unacceptable qualifiers	2					1								
Conveys a promotional message	2	4				1	5	4						
Appears offensive or has a bad connotation	1	1			1									
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations														
Similarity between name of prodrug and related active substance														
Others	2	2	2	1	2	3		5						

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (CPMP/328/98 Rev. 5)* for detailed explanations of criteria used.